← FDA DRUG APPROVALS

FDA ANDA · ANDA210682

OLMESARTAN MEDOXOMIL

Sponsor: CADILA PHARMS LTD

APPLICATION
ANDA210682
TYPE
ANDA
ORIGINAL APPROVAL
2024-11-08
LATEST ACTION
2024-11-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

OLMESARTAN MEDOXOMILPrescription
OLMESARTAN MEDOXOMIL 40MG · TABLET · ORAL
OLMESARTAN MEDOXOMILPrescription
OLMESARTAN MEDOXOMIL 5MG · TABLET · ORAL
OLMESARTAN MEDOXOMILPrescription
OLMESARTAN MEDOXOMIL 20MG · TABLET · ORAL

Approval history

2024-11-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →